CREATE Medicines, a US-based biotech company pioneering in vivo multi-immune programming via proprietary mRNA-LNP CAR platform, has raised $122 million in Series B funding led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners. The platform directly programs T cells, NK cells, and myeloid cells inside the body for scalable, repeat-dose, off-the-shelf immunotherapies with first-in-human validation. The capital will advance its pipeline targeting autoimmune diseases and oncology.
In Vivo CAR Wave Gains Momentum
The timing comes amid surging investor interest in scalable cell therapies. Eli Lilly acquired Orna Therapeutics for $2.4 billion in February 2026. CREATE's multi-lineage approach addresses gaps in ex vivo CAR-T manufacturing and solid tumor penetration.
Ex Vivo Limits Drive In Vivo Shift
Autologous CAR-T therapies require patient-specific cell extraction and high costs, restricting treatment to narrow patient populations despite broad need in cancer and autoimmune conditions.
Multi-Immune mRNA Approach Stands Out
CREATE Medicines programs multiple immune cell types in vivo using mRNA-LNP without viral vectors or preconditioning. It has dosed over 50 patients across programs, building the largest clinical dataset in the in vivo CAR-T field.
As CEO Daniel Getts noted:
"Our autoimmune and oncology pipeline represents the convergence of years of platform development…"
Tier-1 Syndicate Backs Platform
Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners co-led the round. ARCH's history backing gene editing leaders like CRISPR Therapeutics and Intellia Therapeutics validates the technology's potential.
In Vivo CAR-T Market Accelerates
The in vivo CAR-T market is projected to expand from $650 million in 2025 to $10.8 billion by 2034 at 32.9% CAGR. Competitors such as Umoja Biopharma ($500M+ raised) pursue viral vector approaches, while Strand Therapeutics ($150M+) focuses on general mRNA therapeutics.
Pipeline Advances Toward Clinic
First patient dosing in the MT-304 Phase 1/2 study for HER2-positive tumors and advancing CD19 programs for autoimmune disease position CREATE to capture demand for repeat-dosable therapies.